PE20001037A1 - Compuestos heterociclicos como inhibidores de enzimas de rotamasa - Google Patents

Compuestos heterociclicos como inhibidores de enzimas de rotamasa

Info

Publication number
PE20001037A1
PE20001037A1 PE1999000727A PE00072799A PE20001037A1 PE 20001037 A1 PE20001037 A1 PE 20001037A1 PE 1999000727 A PE1999000727 A PE 1999000727A PE 00072799 A PE00072799 A PE 00072799A PE 20001037 A1 PE20001037 A1 PE 20001037A1
Authority
PE
Peru
Prior art keywords
alkyl
alkylene
neureral
immunophyllins
fbkp
Prior art date
Application number
PE1999000727A
Other languages
English (en)
Inventor
Martin James Wythes
Michael John Palmer
Mark Ian Kemp
Mark Allen Sanner
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20001037A1 publication Critical patent/PE20001037A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

SE REFIERE A DERIVADOS DE 1-HETEROARIL-PIRROLIDINA, -PIPERIDINA Y -HOMOPIPERIDINA DE FORMULA (I); DONDE: A ES ALQUILENO C3-C5 OPCIONALMENTE SUSTITUIDO CON ALQUILO C1-C6; X E Y SON O, S, NH, N-ALQUILO C1-C6; R ES UN HETEROCICLO NO AROMATICO DE 4-6 MIEMBROS OPCIONALMENTE CONTIENE UN NITROGENO Y OPCIONALMENTE SUSTITUIDO CON 1-3 ALQUILO C1-C6, ALQUENILO C2-C6, -CONR5R6, ENTRE OTROS; R1, R2, R3 Y R4 SON H, HALOGENO, ALQUILO C1-C6, CICLOALQUILO C3-C7, HALOALQUILO C1-C6, CONR5R6, ENTRE OTROS; R5 Y R6 SON H, ALQUILO C1-C6 O JUNTOS FORMAN ALQUILENO C3-C5, ENTRE OTROS. SON COMPUESTOS PREFERIDOS (2S)-1-(1,3-BENZOXAZOL-2-IL)-N2-[(3S)-1-BENCILPIRROLIDIN-3-IL]-2-PIPERIDINCARBOXAMIDA, (2S)-1-(1,3-BENZOXAZOL-2-IL)-N2-[(3S)-1-(2-PIRIDINILMETIL)PIRROLIDIN-3-IL]-2-PIPERIDINCARBOXAMIDA, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION Y A COMPUESTOS INTERMEDIOS. EL COMPUESTO I ES UN INHIBIDOR DE LA ROTAMASA DE INMUNOFILINAS DE PREFERENCIA LAS INMUNOFILINAS DEL TIPO FBKP-12 Y FBKP-53 POR LO QUE PUEDE SER UTIL PARA EL TRATAMIENTO DE LA DEGENERACION NEURONAL, REGENERACION NEURONAL Y EL CRECIMIENTO NEURONAL COMO DEMENCIA SENIL, ESCLEROSIS LATERAL AMIOTROPICA, ENFERMEDAD DE PARKINSON, ENFERMEDAD DE HUNTINGTON, DEFICIT ASOCIADO CON ACCIDENTES CEREBRO VASCULARES
PE1999000727A 1998-07-21 1999-07-20 Compuestos heterociclicos como inhibidores de enzimas de rotamasa PE20001037A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9815880.1A GB9815880D0 (en) 1998-07-21 1998-07-21 Heterocycles

Publications (1)

Publication Number Publication Date
PE20001037A1 true PE20001037A1 (es) 2000-10-11

Family

ID=10835920

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999000727A PE20001037A1 (es) 1998-07-21 1999-07-20 Compuestos heterociclicos como inhibidores de enzimas de rotamasa

Country Status (45)

Country Link
US (2) US6372736B1 (es)
EP (1) EP1100797B1 (es)
JP (2) JP3795329B2 (es)
KR (2) KR100468185B1 (es)
CN (3) CN1511837A (es)
AP (1) AP2001002046A0 (es)
AR (1) AR019427A1 (es)
AT (1) ATE233261T1 (es)
AU (1) AU765925B2 (es)
BG (1) BG105254A (es)
BR (1) BR9912330A (es)
CA (1) CA2338214C (es)
CO (1) CO5080782A1 (es)
CR (1) CR6073A (es)
DE (1) DE69905582T2 (es)
DK (1) DK1100797T3 (es)
DZ (1) DZ2851A1 (es)
EA (1) EA003513B1 (es)
EE (1) EE200100044A (es)
ES (1) ES2191484T3 (es)
GB (1) GB9815880D0 (es)
GE (1) GEP20033028B (es)
GT (1) GT199900115A (es)
HK (1) HK1039779A1 (es)
HN (1) HN1999000106A (es)
HR (1) HRP20010052A2 (es)
HU (1) HUP0103413A3 (es)
ID (1) ID26991A (es)
IL (1) IL140244A0 (es)
IS (1) IS5790A (es)
MA (1) MA24936A1 (es)
MY (1) MY118222A (es)
NO (1) NO20010322L (es)
NZ (2) NZ508838A (es)
OA (1) OA11585A (es)
PA (1) PA8478501A1 (es)
PE (1) PE20001037A1 (es)
PL (1) PL345734A1 (es)
SI (1) SI1100797T1 (es)
SK (1) SK772001A3 (es)
SV (1) SV1999000102A (es)
TN (1) TNSN99147A1 (es)
TR (1) TR200100135T2 (es)
TW (1) TWI229672B (es)
WO (1) WO2000005232A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9815696D0 (en) * 1998-07-20 1998-09-16 Pfizer Ltd Heterocyclics
GB9815880D0 (en) * 1998-07-21 1998-09-16 Pfizer Ltd Heterocycles
HUP0200312A3 (en) 1998-11-03 2002-12-28 Basf Ag Substituted 2-phenylbenzimidazoles, pharmaceutical compositions containing them, the production thereof and their use
CO5261615A1 (es) 1999-12-01 2003-03-31 Agouron Pharma Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas
FR2805818B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
DE10124953A1 (de) * 2001-05-21 2002-12-12 Marlies Knipper Substanz für die therapeutische Behandlung von Tinnitus
JP4812758B2 (ja) * 2004-06-29 2011-11-09 アベンティス・ファーマスーティカルズ・インコーポレイテツド Fkbp結合組成物及びその医薬上の使用
US7728026B2 (en) * 2005-04-11 2010-06-01 Abbott Laboratories, Inc. 2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors
TWI375673B (en) * 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
EP1957477B1 (en) * 2005-09-29 2011-12-07 Abbott Laboratories 1h-benzimidazole-4-carboxamides substituted with phenyl at the 2-position are potent parp inhibitors
WO2007059230A2 (en) * 2005-11-15 2007-05-24 Abbott Laboratories Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
HUE031972T2 (en) 2005-12-29 2017-08-28 Celtaxsys Inc Diamin derivatives as leukotriene A4 hydrolase inhibitors
GB0602768D0 (en) * 2006-02-10 2006-03-22 Vastox Plc Treatment of muscular dystrophy
RU2462458C2 (ru) * 2006-02-10 2012-09-27 Байомарин Ига Лимитед Лечение миодистрофии дюшена
EP1986633B1 (en) 2006-02-10 2014-07-30 Summit Corporation Plc Treatment of duchenne muscular dystrophy
CN101511821B (zh) * 2006-05-02 2013-07-17 Abbvie公司 取代的1h-苯并咪唑-4-羧酰胺类化合物是有效的parp抑制剂
WO2008079292A1 (en) * 2006-12-20 2008-07-03 Amgen Inc. Heterocyclic compounds and their use in treating inflammation, angiogenesis and cancer
AR065628A1 (es) * 2007-03-07 2009-06-17 Xenon Pharmaceuticals Inc Compuestos triciclicos de utilidad en el tratamiento de trastornos por carencia de hierro en el organismo
US8067613B2 (en) * 2007-07-16 2011-11-29 Abbott Laboratories Benzimidazole poly(ADP ribose)polymerase inhibitors
MX2009012558A (es) * 2007-08-03 2010-04-21 Biomarin Iga Ltd Combinaciones de farmacos para el tratamiento de distrofia muscular de duchenne.
GB0715939D0 (en) * 2007-08-15 2007-09-26 Vastox Plc Method of treatment of duchenne muscular dystrophy
GB0715937D0 (en) * 2007-08-15 2007-09-26 Vastox Plc Method of treatment og duchenne muscular dystrophy
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
WO2010083199A1 (en) * 2009-01-19 2010-07-22 Abbott Laboratories Benzthiazole inhibitors of poly(adp-ribose)polymerase
GB0905664D0 (en) * 2009-04-02 2009-05-13 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
RU2686101C2 (ru) 2013-03-12 2019-04-24 Селтакссис, Инк. Способы ингибирования лейкотриен- а4-гидролазы
AU2014239567B2 (en) 2013-03-14 2017-12-14 Celtaxsys, Inc. Inhibitors of leukotriene A4 hydrolase
BR112015022226A2 (pt) 2013-03-14 2017-07-18 Celtaxsys Inc inibidores de leucotrieno a4 hidrolase
EP2968265A4 (en) 2013-03-14 2016-12-28 Celtaxsys Inc INHIBITORS OF THE LEUKOTRIEN A4 HYDROLASE
MX361606B (es) * 2014-05-19 2018-12-11 Merial Inc Compuestos antihelmínticos.
CA3102077A1 (en) 2018-05-31 2019-12-05 Sanjeev AHUJA Method of reducing pulmonary exacerbations in respiratory disease patients
CN109111376B (zh) * 2018-09-18 2021-09-14 四川医立特生物医药有限公司 一种2,5-双脱氧链霉胺衍生物及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612332A (en) * 1984-03-19 1997-03-18 Alteon Inc. Di- and triaminoguanidines, and methods of use
JPS6428245A (en) 1987-07-22 1989-01-30 Sumitomo Electric Industries Production of fluoride glass
MX9202466A (es) 1991-05-24 1994-06-30 Vertex Pharma Compuestos inmunosupresores novedosos.
CO4520280A1 (es) * 1993-10-26 1997-10-15 Boehringer Ingelheim Pharma Derivados de pirrolidina, inhibidores de la bioscientesis de leucotrienos
DE19514313A1 (de) 1994-08-03 1996-02-08 Bayer Ag Benzoxazolyl- und Benzothiazolyloxazolidinone
US5859031A (en) 1995-06-07 1999-01-12 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
US5696135A (en) * 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
US5801197A (en) * 1995-10-31 1998-09-01 Gpi Nil Holdings, Inc. Rotamase enzyme activity inhibitors
US5786378A (en) * 1996-09-25 1998-07-28 Gpi Nil Holdings, Inc. Heterocyclic thioesters
US5801187A (en) * 1996-09-25 1998-09-01 Gpi-Nil Holdings, Inc. Heterocyclic esters and amides
US5840736A (en) 1996-11-13 1998-11-24 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
US5780484A (en) 1996-11-13 1998-07-14 Vertex Pharmaceuticals Incorporated Methods for stimulating neurite growth with piperidine compounds
US5811434A (en) 1996-11-13 1998-09-22 Vertex Pharmacueticals Incorporated Methods and compositions for stimulating neurite growth
US5721256A (en) 1997-02-12 1998-02-24 Gpi Nil Holdings, Inc. Method of using neurotrophic sulfonamide compounds
GB9815696D0 (en) * 1998-07-20 1998-09-16 Pfizer Ltd Heterocyclics
GB9815880D0 (en) * 1998-07-21 1998-09-16 Pfizer Ltd Heterocycles

Also Published As

Publication number Publication date
DE69905582T2 (de) 2003-09-04
BG105254A (en) 2001-10-31
CO5080782A1 (es) 2001-09-25
HN1999000106A (es) 1999-11-11
MY118222A (en) 2004-09-30
CN1310718A (zh) 2001-08-29
EA003513B1 (ru) 2003-06-26
CN1511837A (zh) 2004-07-14
NZ522270A (en) 2004-03-26
DK1100797T3 (da) 2003-04-22
JP2004002374A (ja) 2004-01-08
SI1100797T1 (en) 2003-06-30
AU4285899A (en) 2000-02-14
NZ508838A (en) 2002-12-20
JP2002521382A (ja) 2002-07-16
CR6073A (es) 2004-04-29
GT199900115A (es) 2001-01-10
BR9912330A (pt) 2001-04-17
US6372736B1 (en) 2002-04-16
IL140244A0 (en) 2002-02-10
CA2338214A1 (en) 2000-02-03
KR100450008B1 (ko) 2004-09-24
SK772001A3 (en) 2001-12-03
AR019427A1 (es) 2002-02-20
HUP0103413A3 (en) 2002-10-28
TR200100135T2 (tr) 2001-06-21
SV1999000102A (es) 2000-07-06
DZ2851A1 (fr) 2004-02-04
DE69905582D1 (de) 2003-04-03
EP1100797B1 (en) 2003-02-26
JP3795329B2 (ja) 2006-07-12
AU765925B2 (en) 2003-10-02
HK1039779A1 (zh) 2002-05-10
AP2001002046A0 (en) 2001-03-31
GB9815880D0 (en) 1998-09-16
WO2000005232A1 (en) 2000-02-03
CA2338214C (en) 2006-08-01
TWI229672B (en) 2005-03-21
ID26991A (id) 2001-02-22
TNSN99147A1 (fr) 2005-11-10
OA11585A (en) 2004-07-26
HRP20010052A2 (en) 2001-12-31
PA8478501A1 (es) 2000-05-24
HUP0103413A2 (hu) 2002-05-29
CN1174978C (zh) 2004-11-10
EA200100052A1 (ru) 2001-06-25
MA24936A1 (fr) 2000-04-01
ATE233261T1 (de) 2003-03-15
KR100468185B1 (ko) 2005-01-26
CN1611499A (zh) 2005-05-04
GEP20033028B (en) 2003-07-25
IS5790A (is) 2000-12-22
KR20010071013A (ko) 2001-07-28
PL345734A1 (en) 2002-01-02
KR20040062640A (ko) 2004-07-07
EE200100044A (et) 2002-06-17
ES2191484T3 (es) 2003-09-01
US6562964B1 (en) 2003-05-13
EP1100797A1 (en) 2001-05-23
NO20010322L (no) 2001-03-15
NO20010322D0 (no) 2001-01-19

Similar Documents

Publication Publication Date Title
PE20001037A1 (es) Compuestos heterociclicos como inhibidores de enzimas de rotamasa
PE59999A1 (es) Derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona-8-sustituidos
UY26872A1 (es) Derivados de la 4- fenil piridina
AR003955A1 (es) Derivados de n-(indol-2-carbonil)-glicinamidas, procedimiento para su obtencion y composiciones que los contienen.
PE110498A1 (es) Tioesteres y cetonas heterociclicos
ATE103812T1 (de) Zusammensetzung zur behandlung von ischaemischen stoerungen in organen.
ATE450514T1 (de) Piperazinylalkylpyrazol-derivate zur verwendung als selektive calciumkanalblocker des t-typs und verfahren zu ihrer herstellung
ATE556712T1 (de) A2a antagonisten zur behandlung von motorischen störungen
PE20040762A1 (es) Ureas substituidas y carbamatos utiles para el tratamiento de la enfermedad de alzheimer
CO4790154A1 (es) Compuestos heterociclicos como inhibidores de enzimas rota- masas
BR9407711A (pt) Composto de ciclopeptídeo processo para preparaçao de um composto de ciclopeptídeo e parasiticida
UY26820A1 (es) Derivados de ciclopentil-glutaramida como inhibidores de endopeptidasa neutra
UY25143A1 (es) Procedimiento para la preparacion de inhibidores de proteasas.
AR002761A1 (es) Un compuesto derivado del triazol, su uso, una composicion farmaceutica que lo contiene, un metodo de tratamiento o prevencion de una infeccion fungica enun paciente humano mediante dicho compuesto o composicion, y procedimiento y compuestos intermedios para prepararlo.
BRPI0409376A (pt) derivados de indeno como agentes farmacêuticos
BR0009389A (pt) Benzoilpirazóis substituìdos como herbicidas
DK0405436T3 (da) Dihetero-nitrogen-holdige cycloheteroethanoanthracenderivater som antipsykotiske midler
PE20000867A1 (es) Inhibidores de las fkbp
KR870011094A (ko) 치환된 피리딘 제초제
MXPA01013148A (es) Nuevos derivados de amonio cuaternario, metodo para la preparacion de los mismos y uso farmaceutico.
PE62099A1 (es) Sulfonamidas n-enlazadas de tioesteres heterociclicos
DE60116656D1 (de) Verfahren zur Herstellung Antibakterieller Verbindungen vom Carbapenem-Typ
DE69900297D1 (de) Akarizid und insektizid wirksame, substituierte Pyrimidine und Verfahren zu ihrer Herstellung
DE69018847T2 (de) Maleimidverbindungen und diese enthaltende Fungizide.
ES2058461T3 (es) Derivados de la 3(2h)-piridazinona, procedimientos para su obtencion y su empleo para la lucha contra las pestes.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed